These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10867304)

  • 1. The combination of phentermine and fenfluramine reduced cocaine withdrawal symptoms in an open trial.
    Kampman KM; Rukstalis M; Pettinati H; Muller E; Acosta T; Gariti P; Ehrman R; O'Brien CP
    J Subst Abuse Treat; 2000 Jul; 19(1):77-9. PubMed ID: 10867304
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of the dopaminergic agent, phentermine, and the serotonergic agent, fenfluramine, in the treatment of cocaine dependence.
    Kampman KM; Volpicelli J
    J Subst Abuse Treat; 1997; 14(4):401-4. PubMed ID: 9368218
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: a preliminary case series.
    Rothman RB
    J Subst Abuse Treat; 1995; 12(6):449-53. PubMed ID: 8749729
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats.
    Halladay AK; Fisher H; Wagner GC
    Alcohol; 2000 Jan; 20(1):19-29. PubMed ID: 10680713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.
    Rothman RB; Redmon JB; Raatz SK; Kwong CA; Swanson JE; Bantle JP
    Am J Cardiol; 2000 Apr; 85(7):913-5, A10. PubMed ID: 10758942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence.
    Kampman KM; Volpicelli JR; Mulvaney F; Rukstalis M; Alterman AI; Pettinati H; Weinrieb RM; O'Brien CP
    Addict Behav; 2002; 27(2):251-60. PubMed ID: 11817766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection.
    Curzon G; Gibson EL
    Adv Exp Med Biol; 1999; 467():95-100. PubMed ID: 10721044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine/serotonin releasers as medications for stimulant addictions.
    Rothman RB; Blough BE; Baumann MH
    Prog Brain Res; 2008; 172():385-406. PubMed ID: 18772043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemoline for the treatment of cocaine dependence in methadone-maintained patients.
    Margolin A; Avants SK; Kosten TR
    J Psychoactive Drugs; 1996; 28(3):301-4. PubMed ID: 8895115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine.
    Glatz AC; Ehrlich M; Bae RS; Clarke MJ; Quinlan PA; Brown EC; Rada P; Hoebel BG
    Pharmacol Biochem Behav; 2002; 71(1-2):197-204. PubMed ID: 11812523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
    Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phentermine/fenfluramine decreases cocaine self-administration in rhesus monkeys.
    Glowa JR; Rice KC; Matecka D; Rothman RB
    Neuroreport; 1997 Apr; 8(6):1347-51. PubMed ID: 9172133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for obesity.
    Boisaubin EV
    JAMA; 1996 Aug; 276(6):445. PubMed ID: 8691540
    [No Abstract]   [Full Text] [Related]  

  • 14. Phentermine and fenfluramine. Preclinical studies in animal models of cocaine addiction.
    Rothman RB; Elmer GI; Shippenberg TS; Rea W; Baumann MH
    Ann N Y Acad Sci; 1998 May; 844():59-74. PubMed ID: 9668665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of phentermine and cocaine on fenfluramine-induced depletion of serotonin in mouse brain.
    Baumann MH; Schuster CR; Rothman RB
    Drug Alcohol Depend; 1996 May; 41(1):71-4. PubMed ID: 8793312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise.
    Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenfluramine and phentermine.
    Howlin D
    Ann Intern Med; 2001 Nov; 135(9):840-1. PubMed ID: 11694113
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine.
    Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC
    Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic induction of weight loss to treat type 2 diabetes.
    Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP
    Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.